Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism? (original) (raw)
The Anatolian Journal of Cardiology
AI-generated Abstract
This case report discusses a 35-year-old patient experiencing heparin-induced thrombocytopenia (HIT) secondary to unfractionated heparin treatment for pulmonary thromboembolism. Following a significant drop in platelet count resulting from HIT, therapy was switched to rivaroxaban, which resulted in an improvement in platelet levels and resolution of thrombotic material. The report suggests that rivaroxaban may serve as a promising treatment option for patients with HIT, although specific treatment guidelines are currently lacking.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.